Media Centre
Latest press releases
-
Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis
-
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
-
FluMist approved for self-administration in the US
-
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
-
Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
